Trial Information
Program for Assessment of Activity and Safety of 1st-line Bevacizumab (Avastin) Therapy in Elderly Patients With Metastatic Colorectal Cancer (BEVERLY-C Study)
Inclusion Criteria:
- Adult patients, >/= 65 years of age
- Patients with newly diagnosed metastatic colorectal cancer starting first-line
treatment with Avastin in combination with fluoropyrimidine-based chemotherapy
according to the approved Hungarian Summary of Product Characteristics
- Patients suitable for Avastin treatment as assessed by the treating physician
Exclusion Criteria:
- Any contraindications to Avastin treatment according to the Hungarian Summary of
Product Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Median progression-free survival
Outcome Time Frame:
approximately 3.5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Hungary: Medical Research Council
Study ID:
ML25630
NCT ID:
NCT01791140
Start Date:
March 2011
Completion Date:
May 2011
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms